Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

1.

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.

Han SW, Cha Y, Paquet A, Huang W, Weidler J, Lie Y, Sherwood T, Bates M, Haddad M, Park IH, Oh DY, Lee KS, Im SA, Bang YJ, Ro J, Kim TY.

PLoS One. 2012;7(7):e39943. doi: 10.1371/journal.pone.0039943. Epub 2012 Jul 27.

PMID:
22848366
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.

Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Köstler WJ, Huang W, Weidler JM, Ali S, Newton A, Fuchs EM, Paquet A, Singer CF, Horvat R, Jin X, Banerjee J, Mukherjee A, Tan Y, Shi Y, Chenna A, Larson J, Lie Y, Sherwood T, Petropoulos CJ, Williams S, Winslow J, Parry G, Bates M.

Breast Cancer Res Treat. 2013 Aug;141(1):43-53.

PMID:
23959396
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group.

N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.

PMID:
23020162
[PubMed - indexed for MEDLINE]
Free Article
4.

Lapatinib for the treatment of HER2-overexpressing breast cancer.

Jones J, Takeda A, Picot J, von Keyserlingk C, Clegg A.

Health Technol Assess. 2009 Oct;13 Suppl 3:1-6. doi: 10.3310/hta13suppl3/01. Review.

PMID:
19846022
[PubMed - indexed for MEDLINE]
Free Article
5.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE.

Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.

PMID:
18188694
[PubMed - indexed for MEDLINE]
6.

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

Scaltriti M, Chandarlapaty S, Prudkin L, Aura C, Jimenez J, Angelini PD, Sánchez G, Guzman M, Parra JL, Ellis C, Gagnon R, Koehler M, Gomez H, Geyer C, Cameron D, Arribas J, Rosen N, Baselga J.

Clin Cancer Res. 2010 May 1;16(9):2688-95. doi: 10.1158/1078-0432.CCR-09-3407. Epub 2010 Apr 20.

PMID:
20406840
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.

Sutherland S, Ashley S, Miles D, Chan S, Wardley A, Davidson N, Bhatti R, Shehata M, Nouras H, Camburn T, Johnston SR.

Br J Cancer. 2010 Mar 16;102(6):995-1002. doi: 10.1038/sj.bjc.6605586. Epub 2010 Feb 23.

PMID:
20179708
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ.

Ann Oncol. 2012 Jun;23(6):1455-64. doi: 10.1093/annonc/mdr445. Epub 2011 Oct 11.

PMID:
21989330
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.

PMID:
21898114
[PubMed - indexed for MEDLINE]
10.

Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.

Crivellari D, Spazzapan S, Lombardi D, Militello L, Torrisi E, Russo AE, Sorio R, Talamini R, Miolo G, Carli P, Veronesi A.

Tumori. 2012 Jan-Feb;98(1):33-8. doi: 10.1700/1053.11497.

PMID:
22495699
[PubMed - indexed for MEDLINE]
11.

Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.

Sperinde J, Jin X, Banerjee J, Penuel E, Saha A, Diedrich G, Huang W, Leitzel K, Weidler J, Ali SM, Fuchs EM, Singer CF, Köstler WJ, Bates M, Parry G, Winslow J, Lipton A.

Clin Cancer Res. 2010 Aug 15;16(16):4226-35. doi: 10.1158/1078-0432.CCR-10-0410. Epub 2010 Jul 27.

PMID:
20664024
[PubMed - indexed for MEDLINE]
Free Article
12.

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies.

Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E.

Br J Cancer. 2014 Apr 15;110(8):1968-76. doi: 10.1038/bjc.2014.72. Epub 2014 Mar 4.

PMID:
24595002
[PubMed - indexed for MEDLINE]
13.

Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.

Arslan UY, Turker I, Aksoy S, Oksuzoglu B, Helvaci K, Yildirim Ozdemir N, Uyeturk U, Uysal Sonmez O, Budakoglu B, Zengin N.

J BUON. 2013 Jul-Sep;18(3):585-93.

PMID:
24065468
[PubMed - indexed for MEDLINE]
14.

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.

BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.

PMID:
21676217
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.

Rhee J, Han SW, Cha Y, Ham HS, Kim HP, Oh DY, Im SA, Park JW, Ro J, Lee KS, Park IH, Im YH, Bang YJ, Kim TY.

Breast Cancer Res Treat. 2011 Jan;125(1):107-14. doi: 10.1007/s10549-010-1200-9. Epub 2010 Oct 9.

PMID:
20936340
[PubMed - indexed for MEDLINE]
16.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

Metro G, Foglietta J, Russillo M, Stocchi L, Vidiri A, Giannarelli D, Crinò L, Papaldo P, Mottolese M, Cognetti F, Fabi A, Gori S.

Ann Oncol. 2011 Mar;22(3):625-30. doi: 10.1093/annonc/mdq434. Epub 2010 Aug 19.

PMID:
20724575
[PubMed - indexed for MEDLINE]
Free Article
17.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

PMID:
22649126
[PubMed - indexed for MEDLINE]
18.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A.

Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.

PMID:
23953056
[PubMed - indexed for MEDLINE]
19.

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.

Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D.

Cancer. 2014 Mar 1;120(5):642-51. doi: 10.1002/cncr.28465. Epub 2013 Nov 12.

PMID:
24222194
[PubMed - indexed for MEDLINE]
20.

[Clinical value of trastuzumab in the treatment of lapatinib-resistant HER2-positive metastatic breast cancer].

Ma F, Xu BH, Li HH, Li Q, Zhang P, Yuan P, Wang JY, Fan Y, Li Q.

Zhonghua Zhong Liu Za Zhi. 2013 Jul;35(7):521-4. Chinese.

PMID:
24257305
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk